0001127602-20-026862.txt : 20201013 0001127602-20-026862.hdr.sgml : 20201013 20201013162007 ACCESSION NUMBER: 0001127602-20-026862 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200915 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spears Michael P CENTRAL INDEX KEY: 0001667779 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 201236511 MAIL ADDRESS: STREET 1: C/O INSULET CORPORATION STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200 CITY: BILLERICA STATE: MA ZIP: 01821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-09-15 0001145197 INSULET CORP PODD 0001667779 Spears Michael P C/O INSULET CORPORATION 100 NAGOG PARK ACTON MA 01720 1 SVP, RA and Compliance Common Stock 2020-09-15 5 G 0 E 2500 0 D 8947 D Common Stock 2020-10-09 4 M 0 13350 29.87 A 22297 D Common Stock 2020-10-09 4 M 0 8907 29.26 A 31204 D Common Stock 2020-10-09 4 S 0 22257 246.10 D 8947 D Employee Stock Option (Right to Buy) 29.87 2020-10-09 4 M 0 13350 0 D 2025-07-27 Common Stock 13350 0 D Employee Stock Option (Right to Buy) 29.26 2020-10-09 4 M 0 8907 0 D 2026-02-24 Common Stock 8907 3735 D The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $244.63 to $251.38. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment. /s/ John W. Kapples, attorney-in-fact 2020-10-13